Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs

Deb, Subrata; Hopefl, Robert

doi:10.1007/s40199-023-00463-1

Cited by 3 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interactions between chemotherapy drugs and other drugs, Chinese herbs, or foods are frequent and severe. [31][32][33][34][35] Létinier et al analyzed the French pharmacovigilance database and found that, of 4,027 reports of adverse reactions caused by drug interactions, 82.02% resulted in serious ADRs. [36] However, the incidence of drug interactions associated with oral chemotherapy agents is currently unknown.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of oral chemotherapeutic drug therapy managed jointly by oncologists and pharmacists

Xue,

Zhang,

Xie

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective: To assess the need for medication therapy management(MTM) from an oncologist/pharmacist joint clinic for patients who self-administer oral chemotherapeutic drugs and to identify intervention programs for pharmacists. Methods: Eighty-three patients who received oral chemotherapy drugs and received medication therapy management(MTM) were assessed by follow-up for three months. Pharmacists reviewed drug indications, use and dosage, oral and written medication education, evaluation of drug interactions, management of adverse drug reactions, medication errors and compliance, improvement and resolution of adverse drug reactions, avoidance of medication errors, and correction of medication compliance. Results: There were 226 follow-up visits and 164 interventions. The management of adverse drug reactions was the most important intervention. There were 655 adverse drug reactions, of which 104 were addressed by intervention and 80 were alleviated or resolved. Eighteen drug interactions were identified, 11 of which were serious drug-drug interactions. Seven medication errors were corrected. Twenty-seven items of medication compliance were managed. Conclusions： Patients who were receiving oral chemotherapy drugs within the standard of care needed additional support, and the medication therapy management(MTM) by pharmacists in the combined oncologist-pharmacist outpatient model could partly meet this need. Early medication therapy management(MTM) interventions may reduce the severity of adverse events, and late medication therapy management(MTM) interventions suggest the need for long-term follow-up management. Further analysis of the cost savings and cost avoidance of pharmacist intervention is necessary to justify the implementation of joint oncologist and pharmacist clinics.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of oral chemotherapeutic drug therapy managed jointly by oncologists and pharmacists

Xue,

Zhang,

Xie

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Physiologically based pharmacokinetic modelling to predict drug–drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors

Kollipara,

Ahmed,

Praveen

2023

Xenobiotica

View full text Add to dashboard Cite

Biomimetic porous silicon for rationally engineered combination therapy to induce immunogenic cell death

Saarela,

Happonen,

Laari

et al. 2024

Preprint

View full text Add to dashboard Cite

Combined chemo-photothermal therapy (CHT-PTT) is a promising treatment for metastatic cancers. It enables the synergistic induction of immunogenic cell death (ICD), while sensitising suppressive tumour microenvironment to immunotherapy. To induce ICD, the rational design of a combined CHT-PTT regimen remains unclear. In the present study, black porous silicon nanoparticles (BPSi NPs) were utilized as both drug carriers and photothermal conversion agents. To enhance their colloidal stability and homotypic targeting, BPSi NP surfaces were modified with polyethylene glycol and further coated with cancer cell membranes (CMs). Six chemotherapeutic drugs with different cell growth inhibition mechanisms were tested against metastatic MDA-MB-231 breast cancer cells to evaluate their ICD induction potentials. Finally, in the combined CHT-PTT, the effect of temperature was evaluated. Based on the analysis of ICD markers, high-mobility group box 1 and calreticulin proteins, we found that bromodomain-containing protein 4 inhibitor, (+)-JQ-1 (JQ1) was the optimal drug, and the mild-hyperthermia temperature of 45 °C was the best temperature setting in the combined CHT-PTT to induce ICD. Thus, our study provides rationally designed CHT-PTT regimen for efficient cancer treatment with high efficacy and low side effects.

show abstract

Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs

Cited by 3 publications

References 28 publications

Evaluation of oral chemotherapeutic drug therapy managed jointly by oncologists and pharmacists

Evaluation of oral chemotherapeutic drug therapy managed jointly by oncologists and pharmacists

Physiologically based pharmacokinetic modelling to predict drug–drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors

Biomimetic porous silicon for rationally engineered combination therapy to induce immunogenic cell death

Contact Info

Product

Resources

About